| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378241 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
The optimization of potent MCHr1 antagonist 1 with respect to improving its in vitro profile by replacement of the 3,4-methylenedioxy phenyl (piperonyl) moiety led to the discovery of 19, a compound that showed excellent MCHr1 binding and functional potencies in addition to possessing superior hERG separation, CYP3A4 profile, and receptor cross-reactivity profiles.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Rajesh R. Iyengar, John K. Lynch, Mathew M. Mulhern, Andrew S. Judd, Jennifer C. Freeman, Ju Gao, Andrew J. Souers, Gang Zhao, Dariusz Wodka, H. Doug Falls, Sevan Brodjian, Brian D. Dayton, Regina M. Reilly, Sue Swanson, Zhi Su, Ruth L. Martin,